Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29728329 | 1.00 | FOLH1 (0.59) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL29728340 | 0.93 | FOLH1 (0.54) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL29728328 | 0.93 | FOLH1 (0.54) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL29728337 | 0.90 | FOLH1 (0.74) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL22590175 | 0.89 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL19065311 | 0.88 | FOLH1 (0.55) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL28902003 | 0.85 | FOLH1 (0.57) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL28902005 | 0.85 | FOLH1 (0.57) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL19065187 | 0.84 | FOLH1 (0.56) | FOLH1PTPN1PAX8TDP1MEN1 | |
| SCHEMBL29728362 | 0.81 | FOLH1 (0.70) | FOLH1PAX8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | FOLH1 2/4885PTPN1 3811/4885PAX8 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.